Ekso Bionics Holdings, Inc.
$11.38
▼
-11.74%
2026-04-21 06:36:00
www.eksobionics.com
NCM: EKSO
Explore Ekso Bionics Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$40.55 M
Current Price
$11.38
52W High / Low
$13.5 / $2.73
Stock P/E
—
Book Value
$2.54
Dividend Yield
—
ROCE
-116.13%
ROE
-1.08%
Face Value
—
EPS
$-4.91
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
50
Beta
0.78
Debt / Equity
51.45
Current Ratio
1.63
Quick Ratio
1.07
Forward P/E
-47.47
Price / Sales
2.51
Enterprise Value
$35.62 M
EV / EBITDA
-3.24
EV / Revenue
2.78
Rating
None
Target Price
$9.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Envista Holdings Corporation | $27.85 | 97.1 | $4.56 B | — | 4.89% | 1.56% | $30.42 / $14.72 | $18.96 |
| 2. | Stevanato Group S.p.A. | $15.86 | 26.32 | $4.33 B | 0.39% | 9.9% | 9.67% | $28 / $12.89 | $6.28 |
| 3. | Bionano Genomics, Inc. | $1.31 | — | $14.53 M | — | -65.83% | -66.15% | $5.5 / $1.06 | $4.14 |
| 4. | Regentis Biomaterials Ltd. | $2.96 | — | — | — | -181.68% | 75.07% | $8.35 / $2.8 | $0.92 |
| 5. | Nyxoah SA | $3.23 | — | $121.16 M | — | -119.32% | -1.11% | $8.87 / $2.35 | $1.33 |
| 6. | Bausch + Lomb Corporation | $16.76 | — | $5.94 B | — | 1.55% | -5.39% | $18.91 / $10.45 | $18.2 |
| 7. | Avantor, Inc. | $8.5 | — | $5.76 B | — | 5.22% | -9.2% | $16.17 / $7.26 | $8.24 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 3.14 M | 4.23 M | 2.06 M | 3.38 M | 5.09 M | — |
| Operating Profit | -4.51 M | -1.4 M | -3.98 M | -3.44 M | -2.23 M | — |
| Net Profit | -4.67 M | -1.42 M | -2.71 M | -2.89 M | -3.41 M | — |
| EPS in Rs | -1.31 | -0.4 | -0.76 | -0.81 | -0.96 | -1.53 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 12.8 M | 17.93 M | 18.28 M | 12.91 M |
| Operating Profit | -13.33 M | -10.46 M | -15.11 M | -15.56 M |
| Net Profit | -11.7 M | -11.33 M | -15.2 M | -15.08 M |
| EPS in Rs | -3.28 | -3.18 | -4.27 | -4.23 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 20.11 M | 26.65 M | 28.92 M | 40.9 M |
| Total Liabilities | 11.08 M | 13.95 M | 16.31 M | 15.46 M |
| Equity | 9.03 M | 12.71 M | 12.61 M | 25.44 M |
| Current Assets | 14.05 M | 18.84 M | 20.21 M | 31.04 M |
| Current Liabilities | 8.64 M | 7.54 M | 8.12 M | 9.2 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -11.8 M | -9.85 M | -12.05 M | -14.69 M |
| Investing CF | -0.19 M | -0.04 M | -0.16 M | -5.17 M |
| Financing CF | 6.63 M | 7.77 M | 0.35 M | 0 M |
| Free CF | -11.99 M | -9.88 M | -12.21 M | -14.88 M |
| Capex | -0.19 M | -0.04 M | -0.16 M | -0.19 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -1.94% | 41.57% | — | — |
| Earnings Growth % | 25.45% | -0.78% | — | — |
| Profit Margin % | -63.21% | -83.14% | -116.79% | — |
| Operating Margin % | -58.35% | -82.67% | -120.48% | — |
| Gross Margin % | 53.06% | 49.67% | 48.13% | — |
| EBITDA Margin % | -52.74% | -72.2% | -108.71% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-06-02 | 1:0.0666667 |